Benign recurrent intrahepatic cholestasis

Clinics in Liver Disease

Volumn 8, Issue 1, 2004, Pages 133-149

  Luketic, Velimir A ^a   Shiffman, Mitchell L ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; ALKALINE PHOSPHATASE; AMINOPHOSPHOLIPID; ANTIHISTAMINIC AGENT; BILE ACID; BILIRUBIN; COLESTIPOL; COLESTYRAMINE; FAMILIAL INTRAHEPATIC CHOLESTASIS 1 PROTEIN; FAT; NALMEFENE; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; PANCREAS ENZYME; PHENOBARBITAL; RIFAMPICIN; S ADENOSYLMETHIONINE; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; VITAMIN K GROUP;

ALKALINE PHOSPHATASE BLOOD LEVEL; AUTOSOMAL RECESSIVE DISORDER; BILIRUBIN BLOOD LEVEL; CELL MEMBRANE FLUIDITY; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; FAMILIAL DISEASE; GENE MUTATION; GENETIC CODE; GENETIC DISORDER; HISTOPATHOLOGY; HUMAN; INTRAHEPATIC CHOLESTASIS; JAUNDICE; LABORATORY; LIPID METABOLISM; LIVER CIRRHOSIS; LIVER INJURY; LOW FAT DIET; MALABSORPTION; MORBIDITY; NONHUMAN; PALLIATIVE THERAPY; PATHOPHYSIOLOGY; PEDIGREE; PHOTOTHERAPY; PLASMAPHERESIS; PRACTICE GUIDELINE; PROGNOSIS; PROTEIN FUNCTION; PRURITUS; RECURRENT DISEASE; REVIEW; SECRETION; SYMPTOM; TOPICAL TREATMENT; TREATMENT INDICATION; ULTRAVIOLET RADIATION; VITAMIN SUPPLEMENTATION;

CHOLESTASIS; HUMANS; RECURRENCE;

EID: 1642319508     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1089-3261(03)00133-8     Document Type: Review

References (94)

1. Summerskill W.H.J., Walshe J.M. Benign recurrent intrahepatic "obstructive" jaundice. Lancet. 2:1959;686-690.
2. Tygstrup N., Jensen B. Intermittent intrahepatic cholestasis of unknown etiology in five young males from the Faroe Islands. Acta Med Scand. 185:1969;523-530.
3. Luketic V.A., Shiffman M.L. Benign recurrent intrahepatic cholestasis. Clin Liver Dis. 3:1999;509-528.
4. Brenard R., Geubel A.P., Benhamou J.P. Benign recurrent intrahepatic cholestasis. J Clin Gastroenterol. 11:1989;546-551.
5. Da Silva L.C., de Brito T. Benign recurrent intrahepatic cholestasis in two brothers. Ann Intern Med. 65:1965;330-341.
6. Kuhn H.A. Intrahepatic cholestasis in two brothers. Ger Med Mon. 8:1963;185-188.
7. Strathers G., Reed C.S.H., Hirst E. Idiopathic recurrent cholestasis. Gastroenterology. 52:1967;536-543.
8. Tygstrup N. Intermittent possibly familial intrahepatic cholestatic jaundice. Lancet. 1:1960;1171-1172.
9. Schapiro R.H., Isselbacher K.J. Benign recurrent intrahepatic cholestasis. N Engl J Med. 268:1963;708-711.
10. De Koning T.J., Sandekujil L.A., De Schryver J.E.A.R.et al. Autosomal-recessive inheritance of benign recurrent intrahepatic cholestasis. Am J Med Genet. 57:1995;479-482.
11. Houwen R.H.J., Baharloo S., Blankenship K.et al. Genome screening by searching for shared segments: mapping a gene for benign recurrent intrahepatic cholestasis. Nat Genet. 8:1994;380-386.
12. De Pagter A.G.F., van Berge Henegouwen G.P., Bokkel-Huinnuk J.A.et al. Familial benign recurrent intrahepatic cholestasis. Gastroenterology. 71:1976;202-207.
13. Lesser P. Benign recurrent intrahepatic cholestasis. Am J Dig Dis. 18:1973;259-264.
14. Tang X., Halleck M.S., Schlegel R.A.et al. A subfamily of P-type ATPases with aminophospholipid transporting activity. Science. 272:1996;1495-1497.
15. Putterman G., Keidar S., Brook J.G. Benign recurrent intrahepatic cholestasis-25 years of follow-up. Postgrad Med J. 63:1987;295-296.
16. Summerskill W.H.J. The syndrome of benign recurrent cholestasis. Am J Med. 38:1965;298-305.
17. Williams R., Carter M.A., Sherlock S.et al. Idiopathic recurrent cholestasis: a study of the functional and pathological lesions in four cases. Q J Med. 33:1964;387-399.
18. Goldberg D.M., Hendry E.B. Familial form of benign idiopathic recurrent cholestasis. Arch Intern Med. 120:1967;556-564.
19. Hopwood D., Read A.E., Williams R. Ultrastructural findings in idiopathic recurrent cholestasis. Gut. 13:1972;986-995.
20. Summerfield J.A., Scott J., Berman M.et al. Benign recurrent intrahepatic cholestasis: studies of bilirubin kinetics, bile acids, and cholangiography. Gut. 21:1980;154-160.
21. Biempica L., Gutstein S., Arias I.M. Morphological and biochemical studies of benign recurrent cholestasis. Gastroenterology. 52:1967;521-535.
22. Endo T., Uchida K., Amuro Y.et al. Bile acid metabolism in benign recurrent intrahepatic cholestasis. Gastroenterology. 78:1979;1002-1006.
23. Spiegel E.L., Schubert W., Perrin E.et al. Benign recurrent intrahepatic cholestasis with response to cholestyramine. Am J Med. 39:1965;682-688.
24. Van Berge Henegouwen G.P., Brandt K.-H., De Pagter A.G.F. Is an acute disturbance in hepatic transport of bile-acids the primary cause of cholestasis in benign recurrent intrahepatic cholestasis? Lancet. 1:1974;1249-1251.
25. Friedman M.R., Holzbach R.T., Ferguson D.R. Pruritus in cholestasis: no direct cause for bile acid retention. Am J Med. 70:1981;1011-1016.
26. Ghent C.N., Bloomer J.R., Klatskin G. Elevations in skin tissue levels of bile acids in cholestasis: relationship to serum levels and to pruritus. Gastroenterology. 73:1977;1125-1130.
27. Minuk G.Y., Shaffer E.A. Benign recurrent intrahepatic cholestasis. Evidence for an intrinsic abnormality in hepatocyte secretion. Gastroenterology. 93:1987;1187-1193.
28. Ishikawa T., Muller M., Klunemann C.et al. ATP-dependent primary active transport of cysteinyl leukotrienes across liver canalicular membrane. J Biol Chem. 265:1990;19279-19286.
29. Kitamura T., Jansen P., Hardenbrook C.et al. Defective ATP-dependent bile canalicular transport of organic anions in mutant (TR-) rats with conjugated hyperbilirubinemia. Proc Natl Acad Sci U S A. 87:1990;3557-3561.
30. Nishida T., Hardenbrook C., Gatmaitan Z.et al. ATP-dependent organic anion transport system in normal and TR-rat liver canalicular membranes. Am J Physiol. 262:1992;G629-G635.
31. Ritt D.J., Combes B. Enhancement of apparent excretory maximum of sulfobromophthalein sodium (BSP) by taurocholate and dehydrocholate. J Clin Invest. 46:1967;1108-1113.
32. Zimniak P., Awasthi Y.C. ATP-dependent transport systems for organic anions. Hepatology. 17:1993;330-339.
33. Bijleveld C.M.A., Vonk R.J., Kuipers F.et al. Benign recurrent intrahepatic cholestasis: altered bile acid metabolism. Gastroenterology. 97:1989;427-432.
34. Heuman D.M., Pandak W.M., Hylemon P.B.et al. Conjugates of ursodeoxycholate protect against toxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes. Hepatology. 14:1991;920-926.
35. Heuman D.M., Mills A.S., McCall J.B.et al. Conjugates of ursodeoxycholate protect against cholestasis and hepatocellular necrosis caused by more hydrophobic bile salts: in vivo studies in the rat. Gastroenterology. 100:1991;203-211.
36. Hylemon P.B. Metabolism of bile acids in intestinal microflora. Danielsson H. Sterols and bile acids. New comprehensive biochemistry. 1985;331-343 Elsevier, Amsterdam.
37. Carleton V.E.H., Kinsley A.S., Freimer N.B. Mapping of a locus for progressive familial intrahepatic cholestasis (Byler disease) to 18q21-q22, the benign recurrent intrahepatic gene. Hum Mol Genet. 6:1995;1049-1053.
38. Oude Elferink R.P.J., Van Berge Henegouwen G.P. Cracking the genetic code for benign recurrent and progressive familial intrahepatic cholestasis. J Hepatol. 29:1998;317-320.
39. Klomp L.W.J., Bull L.N., Juijin J.A.et al. Characterization of multiple different mutations in FIC1 associated with hereditary cholestasis. Hepatology. 30:1999;407A.
40. Van Mil S.W.C., Klomp L.W.J., Bull L.N.et al. FIC1 disease: a spectrum of intrahepatic cholestatic disorders. Semin Liver Dis. 21:2001;535-543.
41. Bull L.N., van Eijk M.J.T., Pawlikowska L.et al. A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis. Nat Genet. 18:1998;219-224.
42. Jacquemin E., Hadchouel M. Genetic basis of progressive familial intrahepatic cholestasis. J Hepatol. 31:1999;377-381.
43. Stautnieks S.S., Bull L.N., Kinsley A.S.et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 20:1998;233-238.
44. Eppens E.F., van Mil S.W.C., de Vree J.M.L.et al. FIC1, the protein affected in two forms of hereditary cholestasis, is localized in the cholangiocyte and the canalicular membrane of the hepatocyte. J Hepatol. 35:2001;436-443.
45. Clayton R.J., Iber F.L., Ruebner B.H.et al. Byler disease: fatal familial intrahepatic cholestasis in an Amish kindred. Am J Dis Child. 117:1969;112-124.
46. Sinke R.J., Carleton V.E.H., Juijin J.A.et al. Benign recurrent intrahepatic cholestasis (BRIC): evidence of genetic heterogeneity and delimitation of the BRIC locus to a 7-cM interval between D18S69 and D18S64. Hum Genet. 100:1997;382-387.
47. Eiberg H., Nielsen I.-M. Linkage of cholestasis familiaris groenlandica/Byler-like disease to chromosome 18. Int J Circumpolar Health. 59:2000;57-62.
48. Klomp L.W.J., Bull L.N., Kinsley A.S.et al. A missense mutation is associated with Greenland familial cholestasis. Hepatology. 32:2000;1337-1341.
49. Nielsen I.-M., Ornvold K., Brock Jacobsen B.et al. Fatal familial cholestatic syndrome in Greenland Eskimo children. Acta Paediatr Scand. 75:1986;1010-1016.
50. Riely C.A. Familial intrahepatic cholestatic syndromes. Suchy F.J. Liver disease in children. 1994;443-459 Mosby, St Louis (MO).
51. Balistreri W.F., A-Kader H.H., Ryckman F.C.et al. Ursodeoxycholic acid therapy in paediatric patients with chronic cholestasis. Lentze M.J., Reichen J. Pediatric cholestasis. Novel approaches to treatment. 1992;333-343 Kluwer Academic Press, Dordrecht (The Netherlands).
52. Lutsenko S., Kaplan J.H. Organization of P-type ATPases: significance of structural diversity. Biochemistry. 34:1995;15607-15613.
53. Ujhazy P., Ortiz D., Misra S.et al. Familial intrahepatic cholestasis 1: studies of localization and function. Hepatology. 34:2001;768-775.
54. Stieger B. FIC1: another bile salt carrier within the enterohepatic circulation? J Hepatol. 35:2001;522-524.
55. Wong M.H., Oelkers P., Craddock A.L.et al. Expression cloning and characterization of the hamster ileal sodium-dependent bile acid transporter. J Biol Chem. 269:1994;1340-1347.
56. Shiffman M.L., Heuman D.H. Pathophysiology and pharmacology of cholestasis. McCallum R.W., Friedman G., Jacobson E.D. Gastrointestinal pharmacology and therapeutics. 1996;401-416 Raven Press, New York.
57. Bergasa N.V., Jones E.A. The pruritus of cholestasis. Semin Liver Dis. 13:1993;319-327.
58. Luketic V.A., Sanyal A.J. Medical therapy of pruritus of cholestasis. Gastroenterologist. 3:1995;257-260.
59. Reichen J. Pharmacologic treatment of cholestasis. Semin Liver Dis. 13:1993;302-315.
60. Grundy S.M., Ahrens E.H., Salen G. Interruption of the enterohepatic circulation of bile acids in man: comparative effects of cholestyramine and ileal exclusion on cholesterol metabolism. J Lab Clin Med. 78:1971;94-121.
61. Bircher J. Treatment of patients with benign recurrent intrahepatic cholestasis. Hepatology. 10:1989;1030-1032.
62. Thornton J.R., Losowsky M.S. Opioid peptides and primary biliary cirrhosis. BMJ. 297:1988;1501-1504.
63. Jones E.A., Bergasa N.V. The pruritus of cholestasis: from bile acids to opiate agonists. Hepatology. 11:1990;884-887.
64. Wolfhagen F.H.J., Sternieri E., Hop W.C.J.et al. Oral naltrexone treatment for cholestatic pruritus: a double-blind, placebo-controlled study. Gastroenterology. 113:1977;1264-1269.
65. Bachs L., Pares A., Montserrat E.et al. Effects of long term rifampicin administration in primary biliary cirrhosis. Gastroenterology. 102:1992;2077-2080.
66. Hoensch H.P., Balzer K., Dylewize P.et al. Effect of rifampicin treatment on hepatic drug metabolism and serum bile acids in patients with primary biliary cirrhosis. Eur J Clin Pharmacol. 28:1985;475-477.
67. Ghent C.N., Carruthers S.G. Treatment of pruritus in primary biliary cirrhosis with rifampin. Gastroenterology. 94:1988;488-493.
68. Cancado E.L.R., Leitao R.M.C., Carrilho F.J.et al. Unexpected clinical remission of cholestasis after rifampicin therapy in patients with normal or slightly increased levels of γ-glutamyl transpeptidase. Am J Gastroenterol. 93:1998;1510-1517.
69. Cacciatore L., Varriale A., Cozzolino G.et al. S-adenosylmethionine in the treatment of pruritus in chronic liver disease. Acta Ther. 15:1989;363-371.
70. Frezza M., Pozzata G., Chiesa L.et al. Reversal of intrahepatic cholestasis of pregnancy in women after high dose S-adenosyl-L-methione administration. Hepatology. 4:1984;274-278.
71. Frezza M., Pozzata G., Pison G.et al. S-adenosylmethionine counteracts oral contraceptive hepatotoxicity in women. Am J Med Sci. 293:1987;234-238.
72. Frezza M., Surrenti C., Manzillo G.et al. Oral S-adenosylmethionine in the symptomatic treatment of intrahepatic cholestasis: a double-blind, placebo-controlled trial. Gastroenterology. 99:1990;211-215.
73. Ribalta J., Reyes H., Gonzalez M.C.et al. S-adenosyl-L-methionine in the treatment of patients with intrahepatic cholestasis of pregnancy: a randomized, double-blinded, placebo-controlled study with negative results. Hepatology. 13:1991;1084-1089.
74. Chawla R.K., Bonkovsky H.L., Galambos J.T. Biochemistry and pharmacology of S-adenosyl-L-methionine and rationale for its use in liver disease. Drugs. 40(Suppl 3):1990;98-110.
75. Boelsterli U.A., Rakhit G., Balazs T. Modulation by S-adenosyl-L- methionine of hepatic Na +, K + -ATPase, membrane fluidity, and bile flow in rats with ethinyl estradiol-induced cholestasis. Hepatology. 3:1983;12-17.
76. Everson G.T., Ahnen D., Harper P.C.et al. Benign recurrent intrahepatic cholestasis: treatment with of S-adenosylmethionine. Gastroenterology. 96:1989;1354-1357.
77. Nakad A., Geubel A.P., Lejeune D.et al. Plasmapheresis: an effective therapy for cholestatic episodes related to benign recurrent intrahepatic cholestasis? Ann Med Interne (Paris). 139:1988;128-130.
78. Cerio R., Murphy G.M., Sladen G.E.et al. A combination of phototherapy and cholestyramine for relief of pruritus in primary biliary cirrhosis. Br J Dermatol. 116:1987;265-267.
79. Maggiore G., Grifeo S., De Giacomo C.et al. Phototherapy for pruritus in chronic cholestasis of childhood. Eur J Pediatr. 139:1982;90-91.
80. Combes B., Carithers R.L. Jr., Maddrey W.C.et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 22:1995;759-766.
81. Fried R.H., Murakami C.S., Fisher L.D.et al. Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver. Ann Intern Med. 116:1992;624-629.
82. Heathcote E.J., Cauch-Dudek K., Walker V.et al. The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology. 19:1994;1149-1156.
83. Lindor K. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis Ursodeoxycholic Acid Study Group. N Engl J Med. 336:1997;691-695.
84. Luketic V.A., Sanyal A.J. The use of ursodeoxycholic acid for the treatment of cholestatic liver disease. Gastroenterologist. 2:1994;74-79.
85. Palma J., Reyes H., Ribalta J.et al. Effects of ursodeoxycholic acid in patients with intrahepatic cholestasis of pregnancy. Hepatology. 15:1992;1043-1047.
86. Persson H., Styrbjorn F., Schersten T.et al. Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients. Lancet. 1:1990;52-53.
87. Poupon R.E., Balkau B., Eschwege E.et al. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med. 324:1991;1548-1554.
88. Poupon R.E., Poupon R., Balkau B. Ursdiol for the long term treatment of primary biliary cirrhosis. The UDCA-PBC study group. N Engl J Med. 330:1994;1342-1347.
89. Calmers Y., Gane P., Rovger P.et al. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology. 11:1990;12-15.
90. 4-3-oxosteroid 5β-reductase deficiency). Hepatology. 18:1993;1096-1101.
91. Bull L.N., Carlton V.E.H., Stricker N.L.et al. Genetic and morphological findings in progressive familial intrahepatic cholestasis (Bylers disease [PFIC-1] and Byler syndrome): evidence for heterogeneity. Hepatology. 26:1997;155-164.
92. Jacquemin E. Progressive familial intrahepatic cholestasis. Clin Liver Dis. 4:2000;753-763.
93. Crosignani A., Podda M., Bertolini E.et al. Failure of ursodeoxycholic acid to prevent a cholestatic episode in a patient with benign recurrent intrahepatic cholestasis: a study of bile acid metabolism. Hepatology. 13:1991;1076-1083.
94. Maggiore G. Efficacy of ursodeoxycholic acid in preventing cholestatic episodes in a patient with benign recurrent intrahepatic cholestasis. Hepatology. 16:1992;504.